Transitional cell carcinoma expresses high levels of Fas ligand in vivo

BJU International

Volumn 83, Issue 6, 1999, Pages 698-702

  Lee, S H ^a   Lee, J Y ^a   Park, W S ^a   Kim, S Y ^a   Jang, J J ^b   Yoo, N J ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Apoptosis; Fas; Fas ligand; Immunohistochemistry; Transitional cell carcinoma

Indexed keywords

FAS LIGAND;

ANTIGEN EXPRESSION; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CELL KILLING; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA;

EID: 0032956260     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1999.00975.x     Document Type: Article

References (32)

1. 1 Dalbagni G, Reuter V, Fair WR, Cordon-Cardo C. Genetic alterations in bladder cancer. Lancet 1995; 342: 469-71
2. 2 Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-65
3. 3 Trauth BC, Klas C, Peters AMJ et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301-5
4. 4 Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surace antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989; 169: 1747-56
5. 5 Suda T, Nagata S. Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med 1994; 179: 873-9
6. 6 Leithäuser F, Dhein J, Mechtersheimer G et al. Constitutive and induced expression of APO-1, a new member of the new grow factor/tumor necrosis receptor superfamily, in normal and neoplastic cells. Lab Invest 1993; 69: 415-29
7. 7 Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-78
8. 8 Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630-2
9. 9 Griffith T, Brunner T, Fletcher S, Green D, Ferguson T. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189-92
10. 10 French LE, Hahne M, Viard G et al. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privilege tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996; 133: 335-43
11. 11 Hunt JS, Vassmer D, Ferguson TA, Miller L. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J Immunol 1997; 158: 4122-8
12. 12 Arai H, Gordon D, Nabel EG, Nabel GJ. Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci USA 1997; 94: 13862-7
13. 13 Lee SH, Jang JJ, Lee JY et al. Fas ligand is expressed in normal skin and in some cutaneous malignancies. Br J Dermatol 1998; 139: 186-91
14. 14 Hahne M, Rimoldi D, Schroter M et al. Melanoma cell expression on fas (apo-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274: 1363-6
15. 15 O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cells expressing Fas ligand. J Exp Med 1996; 184: 1075-82
16. 16 Niehans GA, Brunner T, Frizelle SP et al. Human lung carcinomas express Fas ligand. Cancer Res 1997; 57: 1007-12
17. 17 Bennett MW, O'Connell J, O'Sullivan GC et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998; 160: 5669-75
18. 18 Ungefroren H, Voss M, Jansen M et al. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res 1998: 58: 1741-9
19. 19 Saas P, Walker PR, Hahne M et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 1997; 99: 1173-8
20. 20 Strand S, Hofmann WJ, Hug H et al. Lymphocyte Apoptosis Induced by CD95 (APO-1/Fas) ligand-expressing tumor cells -a mechanism of immune evasion? Nature Med 1996; 2: 1361-6
21. 21 Mostofi FK, Sobin LH, Torloni H. Histological typing of urinary bladder tumors. In International Histological Classification of Tumors. No 10 Geneva: World Health Organization 1973
22. 22 Lee SH, Kim SY, Lee JY et al. Detection of soluble Fas using in situ reverse transcription-polymerase chain reaction. Lab Invest 1998; 78: 453-9
23. 23 Hayashi H, Tatebe S, Osaki M, Goto A, Suzuki Y, Ito H. Expression of Fas antigen and its mediation of apoptosis in human gastric cancer cell lines. Jpn J Cancer Res 1997; 88: 49-55
24. 24 Nambu Y, Hughes SJ, Rehemtula A, Hamstra D, Orringer MB, Beer DG. Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas. J Clin Invest 1998; 101: 1102-10
25. 25 Martin SJ, Green DR. Apoptosis and cancer: the failure of controls on cell death and cell survival. Crit Rev Oncol Hematol 1991; 18: 137-53
26. 26 Sato T, Irie S, Kituda S, Reed JC. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 1995; 268: 411-5
27. 27 Irmler M, Thome M, Hahne M et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190-5
28. 28 Landowsky TH, Qu N, Buyuksal I, Painter JS, Dalton WS. Mutations in the Fas antigen in patients with multiple myeloma. Blood 1997; 90: 4266-70
29. 29 Sulitzeanu D. Immunosuppressive factors in human cancer. Adv Cancer Res 1993; 60: 247-71
30. 30 Cordon-Cardo C, Fuks Z, Drobnjak M et al. Expression of HLA-A, B, C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 1991; 51: 6372-80
31. 31 Gonzalez-Cuadrado S, Lorz C, Garcia del MR et al. Agonistic anti-Fas antibodies induce glomerular cell apoptosis in mice in vivo. Kidney Int 1997; 51: 1739-46
32. 32 Ogasawara J, Watanabe FR, Adachi M et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364: 806-9